Tucatinib hemiethanolate, marketed as Tukysa, is mainly used in combination with other medications to treat HER2-positive advanced or metastatic breast cancer and colorectal cancer. Specifically, it’s used with trastuzumab and capecitabine for breast cancer and with trastuzumab for colorectal cancer, particularly in patients who have previously received other anti-HER2 treatments. It’s also approved for treating colorectal cancer that has spread to other parts of the body and is not operable. It is grouped under the following drug class(es): Kinase inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Tucatinib ethanolate (JAN) and Irbinitinib hemiethanolate. Its PubChem CID is 162623678.
Tucatinib hemiethanolate
| CAS No | 1429755-56-5 |
|---|---|
| Molecular Formula | C54H54N16O5 |
| Molecular Weight | 1007.1 g/mol |
| Synonyms | bis(6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine);ethanol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Tucatinib hemiethanolate, marketed as Tukysa, is mainly used in combination with other medications to treat HER2-positive advanced or metastatic breast cancer and colorectal cancer.
The listed CAS number is 1429755-56-5.
The listed molecular formula is C54H54N16O5.
The listed molecular weight is 1007.1 g/mol.
bis(6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine);ethanol.
The source lists Tucatinib ethanolate (JAN) and Irbinitinib hemiethanolate.